



US009410129B2

(12) **United States Patent**
Ranki et al.

(10) **Patent No.:** **US 9,410,129 B2**
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **RECOMBINANT SEROTYPE 5 (AD5)
ADENOVIRAL VECTORS**

- (71) Applicant: **Targovax Oy**, Helsinki (FI)
- (72) Inventors: **Tuuli Ranki**, Riihimaki (FI); **Akseli Hemminki**, Helsinki (FI); **Vincenzo Cerullo**, Helsinki (FI); **Anniina Koski**, Espoo (FI)
- (73) Assignee: **Targovax Oy**, Helsinki (FI)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

- (21) Appl. No.: **14/359,141**
- (22) PCT Filed: **Nov. 23, 2012**
- (86) PCT No.: **PCT/FI2012/051162**
§ 371 (c)(1),
(2) Date: **May 19, 2014**

- (87) PCT Pub. No.: **WO2013/076374**
PCT Pub. Date: **May 30, 2013**

- (65) **Prior Publication Data**
US 2015/0232811 A1 Aug. 20, 2015

Related U.S. Application Data

- (60) Provisional application No. 61/563,634, filed on Nov. 25, 2011.

(30) **Foreign Application Priority Data**

Nov. 25, 2011 (FI) 20116181

- (51) **Int. Cl.**
C12N 7/00 (2006.01)
A61K 45/06 (2006.01)
A61K 35/761 (2015.01)
- (52) **U.S. Cl.**
CPC **C12N 7/00** (2013.01); **A61K 35/761** (2013.01); **A61K 45/06** (2013.01); **C12N 2710/10021** (2013.01); **C12N 2710/10034** (2013.01)

- (58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,339,068 B1 *	1/2002	Krieg et al.	514/44 R
2003/0138405 A1	7/2003	Fueyo et al.	
2010/0166799 A1	7/2010	Hemminki et al.	
2011/0053893 A1	3/2011	Wu et al.	

FOREIGN PATENT DOCUMENTS

EP	1990418	11/2008
WO	2009127666	1/2009
WO	2010072900	7/2010

OTHER PUBLICATIONS

Mastrangeli, et al. (1996) "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by

changing the adenovirus serotype", *Human Gene Therapy*, 7(1): 79-87.*

Hoffman, et al. (2006) "Restriction of adenoviral replication to the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment", *Molecular Cancer Therapy*, 5(2): 374-81.*

Pesonen, et al. (2012) "Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors" *International Journal of Cancer*, 130: 1937-47.*

Kanerva, et al. (2002) "Targeting Adenovirus to the Serotype 3 Receptor Increases GeneTransfer Efficiency to Ovarian Cancer Cells", *Clinical Cancer Research*, 8: 275-80.*

Dmitriev, et al. (2002) "Engineering of Adenovirus Vectors Containing Heterologous Peptide Sequences in the C Terminus of Capsid Protein IX", *Journal of Virology*, 76(14): 6893-99.*

Kritz, et al. (2007) "Adenovirus 5 Fibers Mutated at the Putative HSPG-binding Site Show Restricted Retargeting with Targeting Peptides in the HI Loop", *Molecular Therapy*, 15(4): 741-49.*

Rein, et al. (2006) "Current developments in adenovirus-based cancer gene therapy" *Future Oncology*, 2(1): 137-43.*

Applicant's publication Cerullo, et al. (2012) "An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance", *Molecular Therapy*, 20(11): 2076-86 is made of record.*

Diaconu et al. "Immune Response is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus", *Cancer Research*, vol. 72, No. 9, Mar. 6, 2012, pp. 2327-2338.

Tillman et al., "Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model", *Cancer Research*, American Association for Cancer Research, US, vol. 60, No. 19, Oct. 1, 2000, pp. 5456-5463.

Jacobelli-Martinez M. et al., "Preferential Activation of Toll-Like Receptor Nine by CD46-Utilizing Adenoviruses", *Journal of Virology*, vol. 81, No. 3, (Nov. 15, 2006), pp. 1305-1312.

Lei N. et al., "An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors", *Cancer Gene Therapy*, vol. 16, No. 1, (Aug. 1, 2008), pp. 33-43.

Wong, Han Hsi et al., "Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles", *Viruses*, vol. 2, No. 1, (Jan. 11, 2010), pp. 78-106.

Supplementary European Search Report issued in EP12852023 and mailed Jun. 22, 2015.

Elmetwali, et al. (2010) "CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus", *Molecular Cancer*, 9: 52, pp. 1-12.

Koski, et al. (2010) "Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF", *Molecular Therapy*, 18(10): 1874-84.

Stoff-Khalili, et al. (2006) "Combining high selectivity of replication via CSCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer", *International Journal of Cancer*, 120: 935-41.

* cited by examiner

Primary Examiner — Robert M Kelly
(74) *Attorney, Agent, or Firm* — Cooley LLP; Matthew Pavao; Ivor Elrifi

(57) **ABSTRACT**

The invention relates to oncolytic adenovirus vectors and their uses in cancer therapy. The adenovirus vectors according to the invention have superior safety properties and have effective therapeutic activity. A production method for the inventive adenoviruses is also disclosed. The adenovirus vectors are useful in cancer therapy.